---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219507"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2026-05-12T20:17:39+00:00"
generated_at: "2026-05-12T20:31:44.872277+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atea Q1 net loss $45.4M ($0.57/shr); HCV Phase 3 topline mid-2026

## Summary
- Net loss $45.4M vs $34.3M YoY; R&D spend rose to $41.1M on HCV Phase 3 and HEV preclinical.
- Cash, equivalents & marketable securities $256.0M at March 31, 2026, down from $301.8M at Dec 2025.
- C-BEYOND HCV Phase 3 (North America) enrollment completed; topline results expected mid-2026.
- C-FORWARD HCV Phase 3 (ex-North America) enrollment on track to complete mid-2026; topline around year-end 2026.
- HEV program: AT-587 selected as lead; in vitro data 30-150x more potent than sofosbuvir/ribavirin; Phase 1 initiation planned mid-2026.

## SEC filing metadata
- accession: 0001193125-26-219507
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2026-05-12T20:17:39+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/0001193125-26-219507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/d12234d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219507
- JSON: https://secwatch.observer/filing/0001193125-26-219507.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219507.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for for the first quarter ended March 31, 2026.
  - Period: for the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 12, 2026, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/0001193125-26-219507-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.